Therapeutic advances of maligmant hematological diseases in 2004 of American
- VernacularTitle:2004年美国血液学恶性疾病治疗研究进展概要
- Author:
Jihong YANG
;
Xuewen WANG
- Publication Type:Journal Article
- Keywords:
Hematology disease;
Targeted therapy;
Hematopoietic cell transplantation
- From:
Journal of Medical Postgraduates
2003;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
In the 46th annual meeting of the American Society of Hematology, the advance in the treatment of maligmant hematological disease concentrats on targeted therapies, including oblimersen,combination therapy rituximab with the chemotherapeutic agent, proteasome inhibitor bortezomid, flavorpiridol and radioimmunotherapy. Hematopoietic cell transplantation (HCT) is an effective therapy of maligmant hematological disease. The foremost advantage of the nonmyeloablative or reduced-intensity HCT is the reduction of treatment-related mortality .
